Pages that link to "Q28748449"

The following pages link to Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline (Q28748449):

Displaying 23 items.

• Bridge between neuroimmunity and traumatic brain injury (Q26827612) (← links)
• Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. (Q27005950) (← links)
• Metabolism in HD: still a relevant mechanism? (Q28394301) (← links)
• (Q28761177) (redirect page) (← links)
• R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures (Q30461090) (← links)
• Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice (Q30489530) (← links)
• A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease (Q30578694) (← links)
• A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI. (Q33769000) (← links)
• Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease (Q33812932) (← links)
• Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease (Q34372919) (← links)
• The role of the immune system in triplet repeat expansion diseases (Q35271805) (← links)
• Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease (Q35754248) (← links)
• The role of immunity in Huntington's disease (Q37868923) (← links)
• Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q. (Q37965763) (← links)
• Animal models of Huntington's disease for translation to the clinic: best practices (Q38248687) (← links)
• A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (Q38383918) (← links)
• Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. (Q38633556) (← links)
• Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies (Q39035495) (← links)
• Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. (Q45290815) (← links)
• TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease (Q45298693) (← links)
• Towards an Understanding of Energy Impairment in Huntington's Disease Brain (Q47442924) (← links)
• The role of multifunctional drug therapy as an antidote to combat experimental subacute neurotoxicity induced by organophosphate pesticides. (Q48234348) (← links)
• Therapy development in Huntington disease: From current strategies to emerging opportunities. (Q53716390) (← links)